Years increasing dividends5.0
#1 of 10063 reported increase years. Years / 10, capped at 5 points.
Nanalyze Dividend
KVUE Kenvue Inc.
Consumer-health brands offer a repeat-demand dividend candidate. Standalone dividend history is short; index membership includes predecessor-history treatment.
Q-score estimate18.6#24 of 100 assessed stocks
Years increasing dividends and dividend yield contribute the most. Payout ratio is the largest constraint. Independent estimate from dated inputs, not a publisher Q-score.
Hypothetical investment
Growth of $10,000
Dividends reinvested · no additional contributions
KVUE would be worth$7,564Available history · 5Y requested · as of Sep 18, 2026
S&P 500 (SPY)$19,637Same $10,000 · same dates
Total gain / loss−$2,436-24.4% total return
KVUES&P 500 (SPY)
May 4, 2023 · $10,000 investedSep 18, 2026
The selected period exceeds this investment’s age; the chart shows its complete available trading history. Based on adjusted market prices through the latest available completed session, before personal taxes and trading costs.
Checking the latest completed session…
Market performance
Total return
Price movement plus reinvested distributions, compared with SPY.
-24.4% over available history
1 YEAR TOTAL RETURN+3.1%#57 return rank · 100 peers
Price-51% of return-1.6%
Dividend151% of return+4.7%
3.3 YEARS TOTAL RETURN-24.4%Since inception-7.9% / yr annualized#91 return rank · 100 peers
Price-33.8%
Dividend+9.4%
Net loss; shares not shown.
Dividend includes all distributions and reinvestment.
May 4, 2023Sep 18, 2026
Total return-24.36%
S&P 500 (SPY)+96.37%
Annualized return-7.94%
Largest drawdown-44.08%
Transparent factor breakdown
Official framework Why the Q-score estimate is 18.6
Each rank compares this stock with the 100 assessed stocks in the Nanalyze collection.
Market capitalization3.1
#61 of 100$36.65 billion. 2 × log10(market cap in USD billions), limited to 0–5 points.
Dividend yield5.0
#1 of 1004.35%. 2 × (yield % − 1.5), limited to −2–5 points.
Payout ratio-0.6
#88 of 10098.51%. (90 − payout %) / 15, limited to −2–5 points. Zero or negative payout receives −2 rather than a false coverage reward.
International sales5.0
#1 of 10050.73% source geographic share. At most 25%: −1 point; above 25% through 50%: 2.5; above 50%: 5. A verified upper bound is usable only when entirely within the lowest band.
5-year dividend growth0.2
#61 of 1005.61%. (5-year growth % − 5) / 3, limited to −2–5 points.
10-year dividend growth0.9
#62 of 1005.71%. (10-year growth % − 4) / 2, limited to −2–5 points.
Independent estimate · assessed October 10, 2026. All 100 research stocks use the same rules. Each component is rounded to one decimal before summing; equal totals share a rank. These scores are not Nanalyze’s published Q-scores. Full method
Supplied Quantigence ALL calculator; imported 2026-09-23; effective date unstated. Quantigence Q-Score Calculator - ALL.csv, row 41; source symbol KVUE. Supplied publisher total: 15.0 (separate scale; not used in this ranking).
Inputs are a supplied calculator snapshot, not live values; its effective date is unstated. Geography and payout definitions are retained as supplied.
The supplied 63-year streak and 5/10-year growth include predecessor history; Kenvue has traded independently only since 2023. These are not standalone company records.
Why it is in this section
Consumer-health brands offer a repeat-demand dividend candidate.
What to investigate
Standalone dividend history is short; index membership includes predecessor-history treatment.
Independent selection; creator ownership or endorsement has not been verified. NOBL screens for a 25-year dividend-increase record; index treatment can include predecessor history. Q-score not assessed.